Summary of risk management 
furoate/vilanterol) 
plan for RELVAR ELLIPTA (fluticasone 
plan (RMP) for RELY AR ELLIPT A. The RMP 
This is a summary of the risk management 
details 
and how 
important risks of RELY AR ELLIPTA, how these risks can be minimised, 
more information will be obtained about RELY AR ELLIPTA risks and uncertainties 
information). 
(missing 
RELY AR ELLIPTA's 
essential 
be used. 
should 
information 
summary 
to healthcare 
of product characteristics 
(SmPC) and its package 
on how RELY AR ELLIPT A 
leaflet 
give 
professionals and patients 
of the RMP for RELY AR ELLIPTA should be read in the context 
This summary 
information including 
the assessment 
all which is part of the European 
Public 
report of the evaluation and its plain-lan
Report (EP AR). 
Assessment 
of all this 
guage summary, 
Important new concerns 
RMP. 
RELYAR ELLIPTA's 
or changes 
to the current 
ones will be included 
in updates of 
I The medicine 
and what it is used for 
treatment 
of asthma in 
adults and 
12 years and older where use of a combination 
(i.e. 
corticosteroid) is 
appropriate 
patients 
not adequately 
medicinal product 
(long-
and inhaled 
already adeq
corticostero
with inhaled 
RELY AR ELLIPTA is authorised for the regular 
adolescents aged 
acting beta-2-agonist 
controlled 
patients 
agonist. RELY AR ELLIPTA 
with a FEY 1 <70% predicted 
regular bronchodilator
fur oate/ vilanterol 
100/25mcg (delive
daily and for COPD: FFNI 100/25mcg 
uately controlled 
ids and 'as needed' inhaled short acting beta-2-agon
ist) and 
beta-2-
and long-acting 
on both inhaled corticosteroid 
for the symptomatic 
is indicated 
normal (post-bronchodilator) with an exacerbation 
fluticasone 
For Asthma: 
It contains 
and it is given by inhalation. 
treatment of adults with COPD 
spite 
 therapy (see SmPC for the full indication). 
as the active substance 
red dose 92/22mcg), FFNI 200/25mcg (delivered 
FFNI 
dose 184/22mcg) once 
history de
(delivered 
dose 92/22mcg) once daily. 
information about the evaluation of 
EP AR, including 
webpage: 
Further 
RELY AR ELLIPTA's 
website, 
https://www.ema.europa.eu/en/me
under the medicine's 
in its plain-language
 summary, 
RELY AR ELLIPTA' s benefits 
dicines/human/EPAR/relvar-e
llipta. 
can be found in 
available on the EMA 
II Risks associated 
the risks 
characterise 
with the medicine 
and activities 
to minimise 
or further 
Important 
the proposed 
risks of RELY AR ELLIPTA together with measures to minimise such risks and 
for learning more about RELY AR ELLIPTA's risks, 
are outlined below. 
studies 
1 
Measures 
to minimise 
the risks 
identified 
for medicinal 
can be: 
products 
• Specific 
information, 
such as warnings, precautions, 
the package 
leaflet 
and SmPC addressed 
to patients 
and advice 
and healthcare 
use, in
on correct 
professionals;
• Important 
advice 
on the medicine's 
packaging;
• The authorised 
pack size - the amount of medicine 
in a pack is chosen so to ensure
that the medicine 
is used correctly;
• The medicine's 
legal status-the 
way a medicine 
its risks.
can help to minimise 
prescription) 
or without 
is supplied 
with
to the patient 
(e.g. 
Together, 
these measures 
constitute 
routine 
risk minimisation 
measures. 
to these measures, 
In addition 
and regularly 
necessary. 
analysed, 
These measures 
about adverse 
PSUR assessment 
is collected 
action 
-so that immediate 
activities. 
pharmacovigilance 
reactions 
constitute 
information 
including 
routine 
continuously 
can be taken as 
If important 
available, 
that may affect the safe use of REL VAR ELLIPT A is not yet 
information' below. 
under 'missing 
information 
it is listed 
II.A List of important 
risks and missing information
risks can be regarded 
or minimise 
Important 
further investigate 
Important 
which there is sufficient 
concerns 
data, but this association 
information 
missing 
risks of REL VAR ELLIPTA are risks that need special 
the risk, so that the medicinal 
as identified 
or potential. 
proof of a link with the use of 
product 
Identified 
for 
risks are 
REL VAR ELLIPT A. Potential 
risks are concerns 
risk management 
to 
activities 
can be safely taken. 
for which an association 
with the use of 
has not been established 
is possible 
this medicine 
yet and needs further evaluation. Missing 
that is currently 
based on available 
product 
refers to 
on the safety of the medicinal 
information 
on the long-term 
(e.g. 
and needs to be collected 
use of the medicine). 
List of important 
risks and missing 
information 
Important 
identified 
risks  Pneumonia 
in patients 
with COPD and asthma 
Important 
potential 
risks  Serious 
cardiovascular 
events 
Corticosteroid-associated 
eye disorders 
Missing 
information Safety 
in pregnancy 
and lactation 
risks
11.B Summary of important 
Important 
Identified 
Risk: Pneumonia 
in patients 
with COPD and 
asthma
Evidence 
medicine 
for linking 
the risk to the 
In two replicate 
in a total 
12 month studies 
(HZC102871 
and HZC102970) 
of 3,255 patients 
with COPD who had experienced 
a 
2
year, there was a higher 
in patients 
receiving 
vilanterol 
hospitalisation occurred 
25 micrograms 
than in those 
combination 
which 
alone (3%). Pneumonia 
in 3% of patients receiving 
and in <1 % of patients 
reported 
in the previous 
(6%-7%) 
(at strengths 
25 micrograms 
furoate/vilanterol 
(all strengths) 
cases of 
In these studies, 
COPD exacerbation 
of pneumonia 
incidence 
the fluticasone 
of 50, 100, and 200 
furoate 
micrograms)/vilanterol 
receiving 
required 
fluticasone 
receiving 
pneumonia 
treatment 
one during 
micrograms 
Risk factors 
current 
patients 
FEV1<50% 
were reported. 
with fluticasone 
treatment 
and one post-treatment 
for pneumonia 
patients 
with fluticasone 
vilanterol. 
predicted. 
observed 
smokers, 
with a history 
with a body mass index <25 kg/m2 and patients 
included 
pneumonia, 
with an 
of prior 
nine fatal 
seven were reported during 
Of these, 
200/25 
furoate/vilanterol 
micrograms, 
furoate/vilanterol 
100/25 
with vilanterol 
in these studies 
monotherapy. 
in SLS-COPD 
of any difference 
FFNI and usual care which included 
The data in SLS-COPD 
are 
(EMA: EMA/H/A-31/1415, 
evidence 
with the PRAG review 
risk between 
and other ICS/LABAs. 
There was no significant 
in pneumonia 
FP/salmeterol 
consistent 
2016), 
in pneumonia 
the treatment 
with placebo, 
of pneumonia. 
risk for different 
of COPD. In SUMMIT, 
there was no meaningful 
which did not find any conclusive 
inhaled 
evidence 
of differences 
corticosteroid 
in 
medicines 
when FFNI was compared 
difference 
in the incidence 
In asthma, 
regardless 
an integrated analysis 
of all 
and patient 
of duration 
suggests 
that asthma 
is an independent 
risk 
showed that the incidence 
groups 
was low 
of pneumonia 
(ISS V2 Doc Ref 2013N187157). 
studies 
evidence 
for pneumonia. 
Recent 
factor 
FFNI clinical 
population 
(<1%) in all treatment 
The calculated 
for FFNI 100/25 
placebo 
evidence 
population. 
arm was observed 
and serious 
pneumonia 
confidence 
intervals 
groups 
treatment 
A slightly 
incidence 
of pneumonia 
years was similar 
subject 
This is in line with literature 
(adjusted 
to 
for exposure) 
(9.3/1000 
of the incidence 
mcg of 8.5/1000 
years). 
of pneumonia 
incidence 
subject 
higher 
reported 
(18.3/1000 subject 
in the general 
in the FFNI 200/25 
mcg 
For both 
years). 
incidences 
calculated, 
all 
across 
were wide and overlapped 
pneumonia 
including 
placebo. 
when analysed 
by current 
In SLS-Asthma, 
incidence 
asthma 
treatment, 
the 
FFNI and other 
between 
care). 
maintenance therapy 
(usual 
of Pneumonia 
was similar 
Risk factors 
and risk groups 
risk factors 
of potential 
analysis 
A detailed 
increased 
hazard 
kg/m2, current 
FEV1<50% 
relationship 
demonstrates 
with VI for BMl<25 
with FFNI compared 
history 
at screening 
of pneumonia 
A BMl�21 kg/m2, also shows a strong 
predicted). 
with event of pneumonia. 
ratios 
smoker, 
and 
3
Both lower BMI and low FEV1 are known risks 
worse outcomes 
with pneumonia. 
for pneumonia 
and 
Risk minimisation 
measures  Routine 
risk minimisation 
measures: 
SmPC section 
Product 
Information). 
4.4 and 4.8, PIL section 
2, 4 (see Approved 
Additional 
risk minimisation 
measures: 
Additional 
None 
pharmacovigilance 
activities 
None 
Important 
Potential 
Risk: Serious 
cardiovascular 
events 
Evidence 
medicine 
the risk to the  Cardiovascular 
studies). 
(in controlled 
events 
for linking 
occurred 
at a similar 
incidence 
to placebo 
groups. 
These 
of FFNI on all-cause 
the risk of an on-treatment 
CV 
effect 
event was similar 
among all treatment 
the lack of a significant 
which is primarily 
driven 
with history 
In SUMMIT (HZC113782), 
composite 
data support 
mortality, 
population 
with VI (as VI alone or FFNI) did not report 
events 
exposure-adjusted 
rate of cardiovascular 
terms in MedDRA SMQs of hypertension, 
cardiac 
cardiac 
and central 
system 
failure, 
haemorrhages 
risk of CV disease, 
a higher 
heart disease, 
ischemic 
and/or 
and cerebrovascular 
by CV mortality. 
In this 
subjects 
treated 
or 
incidence 
(assessed 
by all 
arrhythmia, 
nervous 
conditions). 
In asthma, 
system 
disorder class. 
there were very few adverse 
events 
within 
the cardiac 
Risk factors 
and risk groups 
Older age, a history 
function 
in the COPD population. 
cardiac 
of increased 
were predictive 
of previous 
disease 
and worse lung 
risk of cardiovascular 
events 
Risk minimisation 
measures  Routine 
risk minimisation 
measures: 
SmPC section 
Information). 
4.4, PIL section 
2, 3, 4 (see Approved 
Product 
Additional 
risk minimisation 
measures: 
Additional 
None 
pharmacovigilance 
activities 
None 
4 
Important 
Potential 
Risk: Corticosteroid-associated 
eye disorders 
Evidence 
medicine 
for linking 
the risk to the  This is considered 
associated 
In the COPD placebo 
products. 
a class risk for !CS-containing 
There 
during 
events 
lung function 
controlled 
across 
reported 
adverse 
and these were distributed 
In the COPD one year 
arms, including 
studies, 
placebo. 
the incidence 
arms, and there was no clear difference 
was similar 
between 
of events 
across 
FF, than in the VI monotherapy 
rate in this population. 
associated 
placebo. 
of corticosteroid 
arms including 
are likely 
the 
to represent 
the 
In the SUMMIT study, 
eye disorders 
was similar 
at least 
treatment 
on arms containing 
arm. These events 
studies. 
these were few events, 
were few ocular 
clinical 
studies 
the treatment 
exacerbation 
treatment 
events 
treatment 
background 
incidence 
across 
experiencing 
subjects 
interest 
special 
similar 
between 
associated 
adverse 
the one year safety 
examinations, 
Version 
horizontal 
the Minimum 
Screening, 
measures, 
considered 
cataract 
100/25 
including 
formation. 
and FFNI 200/25 
cup-to-disc 
including 
Ill (LOCS 111) lens grades, 
ratio, 
acuity 
Angle of Resolution (LogMAR), 
pressure 
(IOP), 
of 
using Logarithm 
at 
were performed 
intraocular 
and visual 
Week 28 and Week 52. Of these ophthalmic 
the posterior 
to be the most relevant 
The results 
assessment 
of this study showed that FFNI 
subcapsular 
(P) lens grade is 
opacity 
of drug-related 
had no apparent 
ophthalmic 
effects, 
lens opacification 
and IOP. 
one ADR/ one serious 
associated 
The proportion 
of 
AE of 
eye disorders 
arms. There were few ocular 
was 
of corticosteroid 
the two treatment 
events 
reported 
study (HZA106839) 
Lens Opacities 
during 
In 
the Asthma studies. 
Ophthalmic 
Classification System, 
Risk factors 
and risk groups 
As a clear association 
demonstrated 
determine 
with inhaled 
any specific 
with glaucoma 
has not been 
corticosteroids, 
and cataract 
to 
it is not possible 
risk factors. 
It can be assumed 
glaucoma 
influences. 
that those patients 
with a predisposition 
for 
or cataract 
may be more at risk from any additional 
Risk minimisation 
measures  Routine 
risk minimisation 
measures: 
SmPC section 
Information). 
4.4, PIL section 
2, 4 (see Approved 
Product 
Additional 
risk minimisation 
measures: 
Additional 
None 
pharmacovigilance 
activities 
None 
5
Missing 
information: 
Safety 
in pregnancy 
and lactation 
Risk minimisation 
measures  Routine 
risk minimisation 
measures: 
SmPC section 
Information). 
4.6 and PIL section 
2 (see Approved 
Product 
Additional 
risk minimisation 
measures: 
None 
11.C Post-authorisation 
development 
plan
11.C.I 
Studies 
which are conditions 
of the marketing 
authorisation
There are no 
studies 
REL VAR ELLIPTA. 
that are conditions 
of the marketing 
of 
authorisation or 
obligation 
specific 
11.C.2 
Other studies 
in post-authorisation 
development 
plan
There are no 
studies 
required 
for REL VAR ELLIPTA. 
6
